Does TOLVAPTAN Cause Hyperparathyroidism secondary? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Hyperparathyroidism secondary have been filed in association with TOLVAPTAN (Jynarque). This represents 0.1% of all adverse event reports for TOLVAPTAN.
6
Reports of Hyperparathyroidism secondary with TOLVAPTAN
0.1%
of all TOLVAPTAN reports
0
Deaths
3
Hospitalizations
How Dangerous Is Hyperparathyroidism secondary From TOLVAPTAN?
Of the 6 reports, 3 (50.0%) required hospitalization.
Is Hyperparathyroidism secondary Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOLVAPTAN. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does TOLVAPTAN Cause?
Death (800)
Thirst (624)
Off label use (560)
Renal impairment (534)
Underdose (448)
Product use in unapproved indication (446)
Wrong technique in product usage process (426)
Polyuria (390)
Product dose omission issue (379)
Inappropriate schedule of product administration (376)
What Other Drugs Cause Hyperparathyroidism secondary?
ESOMEPRAZOLE (1,357)
OMEPRAZOLE (1,274)
PANTOPRAZOLE (947)
LANSOPRAZOLE (888)
DEXLANSOPRAZOLE (382)
RABEPRAZOLE (108)
DENOSUMAB (60)
FUROSEMIDE (49)
OMEPRAZOLE\SODIUM BICARBONATE (48)
ESOMEPRAZOLE\NAPROXEN (47)
Which TOLVAPTAN Alternatives Have Lower Hyperparathyroidism secondary Risk?
TOLVAPTAN vs TOPAMAX
TOLVAPTAN vs TOPIRAMATE
TOLVAPTAN vs TOPOTECAN
TOLVAPTAN vs TOPOTECAN\TOPOTECAN
TOLVAPTAN vs TOPROL